Aptevo Therapeutics Inc. (APVO) — 10-Q Filings

10-Q Filings (6)

• Aptevo's Losses Widen Amid Increased R&D, Bolstered by Equity Raises — Nov 6, 2025 Risk: high
  Aptevo Therapeutics Inc. reported a net loss of $7.549 million for the three months ended September 30, 2025, an increase from $5.101 million in the same period
• Aptevo Navigates Pre-Revenue Stage with Aggressive Capital Raises — Aug 11, 2025 Risk: high
  Aptevo Therapeutics Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commer
• Aptevo Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Aptevo Therapeutics Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information, including retained earnings and additional
• Aptevo Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Aptevo Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition, including details on common s
• Aptevo Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Aptevo Therapeutics Inc. filed its 10-Q for the period ending June 30, 2024. The company's fiscal year ends on December 31st. Key financial data and business ac
• Aptevo Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — May 8, 2024 Risk: medium
  Aptevo Therapeutics Inc. (APVO) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Aptevo Therapeutics Inc. filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX